BGHL (GBP): NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
80
BGHL (GBP): NAV(s)

                                      BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 17 Aug 2018.

 

Estimated NAV

 

  Euro Shares Sterling Shares
Estimated NAV €  22.7354 £  20.2029
Estimated MTD return  -0.73 %  -0.67 %
Estimated YTD return  -3.03 %  -2.44 %
Estimated ITD return  127.35 %  102.03 %

 

NAV and returns are calculated net of management and performance fees

 

Market information

 

Euro Shares Amsterdam (AEX) London (LSE)
Market Close €  19.00 N/A
Premium/discount to estimated NAV  -16.43 % N/A
     
Sterling Shares Amsterdam (AEX) London (LSE)
Market Close N/A GBX 1,720.00
Premium/discount to estimated NAV N/A  -14.86 %

 

 

Transactions in own securities purchased into treasury

 

Ordinary Shares Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A
Range of Price N/A N/A

           

                                           

Liquidity Enhancement Agreement Euro Shares Sterling Shares
Number of shares N/A N/A
Average Price N/A N/A

 

BGHL Capital

 

BGHL Ordinary Shares Euro Shares Sterling Shares
Shares Outstanding  28,758,219  632,590
Held in treasury N/A N/A
Shares Issued  28,758,219  632,590

 

Estimated BG Fund NAV

Class B Euro Shares (estimated) €  183.4722

The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.

 

For further information please contact:

Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

 

 

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 35

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 51

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 119

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 291

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 0

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Reactions: Middle East Tensions and the Vance-Walz Debate

Updated Category News Views 71

Market Reactions to Middle East Tensions US stock futures are experiencing a downward trend as investors react to the escalating violence in the Middle East. With Iran claiming to have ceased its air bombardments on Israel, uncertainty still looms, as Israeli officials pledge a counterattack. This ongoing conflict has already impacted Wall Street, where equity values...

Continue Reading
Class Action Alert for Visa Inc. Shareholders Facing Losses

Updated Category News Views 91

Class Action Notification for Visa Inc. Shareholders The Gross Law Firm is reaching out to shareholders of Visa Inc. (NYSE: V) regarding an important class action that may affect them. If you purchased shares during a specific class period and have suffered losses, your participation could be significant in holding the company accountable. Understanding the Class Period...

Continue Reading
Coca-Cola's Earnings Report: Anticipated Insights and Analysis

Updated Category News Views 205

Coca-Cola's Earnings Report Overview The Coca-Cola Company (NYSE: KO) is on the cusp of unveiling its second-quarter financial results. Investors, analysts, and fans alike are closely watching what insights the beverage giant will provide during this crucial report. With notable figures in the U.S. market keeping an eye on Coca-Cola, the anticipation is palpable. Earnings...

Continue Reading
Maggiano's Unveils Gourmet Italian-American Classics Menu

Updated Category News Views 410

Introduction of Italian-American Classics at Maggiano's Maggiano's Little Italy is embracing the culinary heritage of Italian-American cuisine by introducing a new menu that reflects a dedication to high-quality ingredients and gourmet recipes. Under the expert guidance of award-winning Chef Anthony Amoroso, the restaurant's latest offerings promise to impress food...

Continue Reading
Recognizing Excellence: Pierce & O'Neill Founders Honored

Updated Category News Views 362

Pierce & O’Neill Founders Honored Among Top Attorneys Pierce & O’Neill, LLP, a renowned litigation boutique, is celebrating its founders, Jesse Pierce and Jack O’Neill, for their remarkable achievements in the legal field. Recently recognized in Lawdragon’s prestigious list of the 500 Leading Lawyers in America for 2025, this accolade showcases their exceptional...

Continue Reading